SILVERCREST ASSET MANAGEMENT GROUP LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 425 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.2%.

Quarter-by-quarter ownership
SILVERCREST ASSET MANAGEMENT GROUP LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$24,183,427
+29.9%
633,074
+22.6%
0.18%
+38.3%
Q2 2023$18,618,252
+42.8%
516,170
+51.2%
0.13%
+34.3%
Q1 2023$13,033,598
-44.5%
341,283
-17.3%
0.10%
-45.0%
Q4 2022$23,479,216
+35.4%
412,640
-5.9%
0.18%
+25.9%
Q3 2022$17,340,000
+2.7%
438,541
+14.2%
0.14%
+11.7%
Q2 2022$16,890,000
+44.9%
383,854
+31.3%
0.13%
+68.4%
Q1 2022$11,658,000
+3211.9%
292,328
+3237.8%
0.08%
+3700.0%
Q4 2021$352,000
+10.0%
8,758
+11.2%
0.00%0.0%
Q3 2021$320,000
+1.3%
7,878
+13.2%
0.00%0.0%
Q2 2021$316,000
+11.3%
6,960
+2.0%
0.00%0.0%
Q1 2021$284,000
+0.7%
6,822
+3.3%
0.00%0.0%
Q4 2020$282,0006,6010.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Third Security, LLC 19,305,403$233,209,00010.86%
BB BIOTECH AG 7,379,832$89,148,0003.13%
SENZAR ASSET MANAGEMENT, LLC 550,544$6,650,572,0001.72%
SNYDER CAPITAL MANAGEMENT L P 2,232,114$26,964,0001.69%
Sterling Global Strategies LLC 22,000$266,0000.98%
IRIDIAN ASSET MANAGEMENT LLC/CT 9,290,024$112,223,0000.98%
MSD Partners, L.P. 965,000$11,657,0000.94%
DOHENY ASSET MANAGEMENT /CA 130,950$1,582,0000.81%
Taylor Wealth Management Partners 128,110$1,548,0000.69%
Bellevue Group AG 318,000$3,841,0000.69%
View complete list of HALOZYME THERAPEUTICS INC shareholders